Background/Aims: Disseminated tumors, known as metastases, are responsible for ninetypercent of mortality due to cancer. Epithelial to mesenchymal transition, a phenomenon required for morphological conversion of non-motile discoid shaped epithelial cells to highly motile spindle-shaped mesenchymal cells, is thought to be a pre-requisite for metastatic progression. Metastasis-associated 1 (MTA1) protein is a prime inducer of EMT and metastatic progression in all solid tumors including hepatocellular carcinoma (HCC). However, the molecular mechanisms that regulate the expression and function of MTA1 in HCC have not been elucidated. Methods: In silico prediction algorithms were used to find microRNAs (miRNAs) that may target MTA1. We examined the relationship between the expression of MTA1 and miR-183 using quantitative real time PCR. We also determined the levels of the MTA1 protein using immunohistochemistry. Reporter assays, in the presence and absence of the miR-183 mimic, were used to confirm MTA1 as a bona fide target of miR183. The effect of miR-183 on HCC pathogenesis was determined using a combination of in vitro migration and invasion assay, together with in vivo xenograft experiments. The correlation between miR-183 and MTA1 expression was also studied in samples from HCC patients, and in The Cancer Genome Atlas dataset. Results: Analysis of the sequence database revealed that MTA1 is a putative target of miR-183. MTA1 protein and RNA expression showed opposite trends to miR-183 expression in breast, renal, prostate, and testicular tissue samples from cancer patients, and in the metastatic HCC cell line HepG2. An inverse correlation was also observed between MTA1 (high) and miR-183 (low) expression within samples from HHC patients and in the TCGA dataset. Reporter assays in HepG2 cells showed that miR-183 could inhibit translation of a reporter harboring the wild-type, but not the mutant miR-183 3'-untranslated region (UTR). In addition, miR-183 significantly inhibited in vitro migration and invasion in HepG2 cells, and in 
Introduction
The incidence of hepatocellular carcinoma (HCC) is increasing. It has become a frequently encountered form of solid cancer [1] [2] [3] . Advances made over the last two decades are aiding early diagnosis, therapy, and surgical management; unfortunately, however, all efforts have so far failed to contain HCC -due to its high propensity to metastasize to secondary organs and its resistance to chemotherapy [4, 5] . Therefore, it is important to identify prognostic and diagnostic molecular markers in HCC.
The metastasis-associated (MTA) gene family -has three members, namely MTA1, MTA2 and MTA3 [6] . MTA1 is an intrinsic component of the nucleosome remodeling and histone deacetylation complex and can function as a transcription factor [7, 8] . Importantly, MTA1 is a central regulator of epithelial-mesenchymal transition (EMT) [7] . It has been shown that MTA1 overexpression leads to a poor outcome in patients with malignant tumors [9, 10] . However, what precisely regulates MTA1 expression is not currently known; although it has been found that the estrogen receptor alpha (ERα) inhibits MTA1 transcription and, as a result, retards invasion and proliferation during HCC pathogenesis [11] .
MicroRNAs, a group of endogenous, small noncoding RNAs, can regulate numerous normal cellular pathways as well as aberrant processes during tumor pathogenesis. MicroRNAs can inhibit target gene function by either promoting degradation of the mRNA or by suppressing its translation, with the degree of complementarity between the miRNA and target mRNA sequences directing which of the two modes of inhibition will take effect [12] . MiRNAs possess both tumor suppressive and oncogenic functions [13] ; a great deal of work is needed to understand why and how they influence tumor progression. The objective of this study was to determine whether miRNAs regulate MTA1 expression in HCC.
Materials and Methods

Patients and tissue processing
The study design was approved by the Institutional Review Board of the Second Hospital of Hebei Medical University, China. Either paraffin-embedded or fresh snap frozen samples with a pathological diagnosis of breast, renal, prostate, and testicular tissue specimens (n = 10 per cancer type) were obtained from Chinese cancer patients at the Second Hospital of Hebei Medical University between 2014 and 2015. We chose patients for inclusion based on confirmed diagnosis, no prior adjuvant or chemotherapy, availability of follow-up, and clinical data. Freshly harvested tissue specimens were equilibrated with RNAlater (Life Technologies, Shanghai, China) before being snap frozen. All samples were stored in liquid nitrogen tanks for long-term storage.
Cell culture
HepG2 cell line was obtained from ATCC (Beijing Zhongyuan Ltd, Beijing, China). Media for HepG2 was FBS (10%, Lonza, Germany) and penicillin/streptomycin (ThermoFisher Scientific, Shanghai, China) supplemented with Dulbecco's Modified Eagle Medium (DMEM) (ThermoFisher Scientific).
Isolation of RNA and miRNA extraction and quantitative real time polymerase chain reaction (qRT-PCR)
RNA was isolated using Trizol (ThermoFisher Scientific) according to the manufacturer's protocol. The following TaqMan Gene Expression probes (ThermoFisher Scientific) were used for qRT-PCR: MTA1 (TaqMan Assay ID: Hs00950776_m1) and TBP (TaqMan Assay ID: Hs00427620_m1). Data analysis was performed using the -ΔΔCt method. Relative changes were normalized to TBP expression. The mirVana miRNA isolation kit (ThermoFisher Scientific) was used to isolate miRNA. The following TaqMan miRNA Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry assay probes were used for qRT-PCR: miR-183 (TaqMan Assay ID: 002270) and RNU6B (TaqMan Assay ID: 001093). The latter was used for data normalization.
Immunohistochemistry
Tissue specimens from representative patients (n= 3 in each case) with breast, renal, prostate and testicular carcinoma with high and low miR-183 levels were stained for MTA1 expression (#ab-71153, Abcam, Cambridge, UK). A score of 'low' or 'high' was assigned to each specimen by a pathologist blinded to the identity of the specimens.
Gene construction
The MTA1 3' UTR was cloned into the XhoI and ApaI sites in the Rr-luc-6XCXCR4 Renilla luciferase vector (Addgene, Beijing Zhongyuan Ltd. Beijing, China). Site-directed mutagenesis was used to delete the 321-327 region, corresponding to the hsa-miR-183 binding site, in the reporter plasmid. For transfection control, a firefly luciferase gene, not under the control of MTA1 3'UTR, was used.
Transfection and luciferase assays
HepG2 cells were transiently transfected with Rr-luc-6XCXCR4 Renilla luciferase vector using Lipofectamine 2000 (ThermoFisher Scientific) according to the manufacturer's protocol. For the mimics, the cells were also co-transfected with either C-X-C chemokine receptor type 4 (CXCR-4) or the miR-183 mimic (ThermoFisher Scientific). Luciferase assays were performed 96 hours after transfection, using the Dual-luciferase assay kit (Promega, Madison, Wisconsin, USA). Results shown are from three biological replicates, each performed with three technical replicates. Data are shown as relative fluorescence units (RFU) ± standard deviation (SD).
Cell proliferation assay
The MTT assay kit (Sigma-Aldrich, Shanghai, China) was used to determine cell proliferation quantitatively. Results, shown as relative optical density (OD) (mean ± standard deviation), are from three biological replicates, each performed with three technical replicates.
Trans-well migration and invasion assays
Migration and invasion assays were performed using Culture kits (R&D Systems, Shanghai, China). Results shown are from three biological replicates, each carried out with three technical replicates.
Xenograft assay
The Institutional Animal Care and Use Committee of the Second Hospital of Hebei Medical University approved all animal studies performed and reported in this manuscript. FF-HepG2 cells (10 6 ), transfected with the miR-182 or CXCR4 mimic, were injected subcutaneously into the hind-flank of six-week-old female nude mice (n=5 per group). Tumor formation and metastasis were followed for 35 days after the surgery using in vivo bioluminescence imaging (IVIS Imaging System PerkinElmer, Waltham, USA). The same number (10 6 ) of HepG2 cells were injected into the right lower lobe of the livers in mice (n=5) to assess metastasis. Animals were sacrificed on day 56, and tumor nodules counted in the left lobe.
Results
The TargetScan and microCosm algorithms were used to find miRNAs that might target MTA1. MiR-183 was one of the predicted miRNAs (Fig. 1A) . Importantly, the miR-183 target site within the MTA1 3'UTR was conserved across species (Fig. 1B) .
To estimate the expression of MTA1 in tumor specimens with high and low miR-183 expression levels, we surveyed 10 pairs of tumor and adjacent normal tissue samples from breast, renal, prostate, and testicular cancers for miR-183 expression. Following identification of low and high expressing specimens, we performed immunohistochemistry on representative samples. Significantly higher MTA1 expression was detected in tumor specimens with low miR-183 levels than in those with high miR-183 expression, suggesting that MTA1 may be a putative target of miR-183 (Fig. 2) , suggesting that MTA1 might be a putative target of miR-183. We then set out to prove that MTA1 is indeed a target of miR-183. We evaluated HCC cell lines for miR-183 and MTA1 expression. One of the cell lines that had a suppressed miR-183 expression (-12.8 ± 0.3 fold) and a correspondingly high MTA1 expression (+3.1 ± 0.4 fold) was HepG2 (Fig. 3A) . To confirm the interaction between miR-183 and the 3'UTR of MTA1, we transfected renilla reporter plasmids harboring the MTA1 3′UTR into HepG2 cells, either alone or with the miR-183 mimic (Fig. 3B) . The miR-183 mimic suppressed reporter activity of the MTA1 3'UTR by 4.6 ± 0.05 fold (P = 0.004) in HepG2 cells. In contrast, upon testing a miR-183 binding mutant of the MTA1 3'UTR reporter (in which nucleotides 321-327 -the miR-183 binding site -were deleted), we found that the miR-183 mimic could no longer repress the mutant reporter activity (p>0.05) (Fig. 3B) , confirming MTA1 as a direct target of miR-183.
Transfection with miR-183 mimic did not suppress cell proliferation after day 1 (CXCR vs miR-183 mimic -0.67 ± 0.04 vs 0.68 ± 0.05, p>0.05), day 2 (CXCR vs miR-182 mimic -1.13 ± 0.04 vs 0.43 ± 1.13, p>0.05), and day 3 (CXCR vs miR-182 mimic -2.04 ± 0.06 vs 2.04 ± 0.09, p>0.05) (Fig. 4A) .
HepG2 cells transfected with CXCR4 or miR-183 mimic were used to measure in vitro migration (Fig. 4B) and invasion (Fig. 4C) assays. Overexpression of miR-183 inhibited in vitro migration (CXCR vs miR-183 mimic -75 ± 3 vs 25 ± 2, p<0.05), and invasion (CXCR vs miR-183 mimic -73 ± 5 vs 21 ± 4, p<0.05). The results indicated that decreased levels of miR-183 would lead to increased in vitro migration and invasion in HCC cells, through the upregulation of MTA1. Taken together, the decrease in the relative expression of miR-183 and the corresponding increase in MTA1 expression in HCC tissues or cell lines, along with its capacity to regulate in vitro migration and invasion implied that miR-183 could potentially inhibit tumorigenesis and metastatic progression in HCC [14] .
We used HepG2 cells stably overexpressing CXCR4 mimic or miR-183 mimic in a subcutaneous xenograft assay to assess the in vivo consequences of high miR-183 expression on tumor growth. Our results showed that ectopic overexpression of miR-183 in the HepG2 cells significantly inhibited tumor growth rate (Fig. 5A ) (P<0.01) and decreased tumor burden (data not shown), compared to the HepG2/CXCR4 mimic xenografts. Using a hepatic tumor growth model, we then determined whether miR-183 also regulated metastasis in HCC. We found that the stable overexpression of miR-183 in HepG2 cells downregulated formation of hepatic tumor nodules in the non-injected liver lobes (Fig. 5B) . The present results indicating that miR-183 functions as a tumor suppressor in HCC is consistent with its action of downregulating MTA1, which is both pro-tumorigenic and pro-metastatic in HCC. Finally, we performed metagenomic analysis of The Cancer Genome Atlas (TCGA) data and identified an inverse correlation between MTA1 expression and miR-183 expression (Fig. 6A) . In fact, when we determined miR-183 and MTA1 expression in 25 HCC patients, the results indicated an inverse relationship between the levels of miR-183 and that of MTA1 in HCC tissue specimens (Fig. 6B) (P < .005, Pearson correlation r = -0.8318). 
Figure 4
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Discussion
The present results showed that miRNA-183 and MTA1 expression are inversely regulated in multiple human cancers including HCC and indicate that miRNA-183 acts by downregulating MTA1. Increasing the levels of miRNA-183 through transfection by a mimic did not affect cell proliferation but suppressed in vitro migration and invasion, as well as well as in vivo tumorigenesis and metastatic potential in the HepG2 HCC cell line. Thus, the present results establish miR-183 as a tumor suppressor in HCC. Given that the current study focused on patients without any prior surgical or therapeutic intervention, it will be important to examine and understand how such interventions affect the balance between miR-183 and MTA1 expression in patients with HCC. Furthermore, it will be clinically relevant to investigate if replenishment of miR-183 to levels observed in normal hepatocytes would increase the susceptibility of HCC cells to chemotherapy.
The unique aspect of miRNAs is that they can function both as tumor suppressors as well as oncomirs in a context-dependent fashion [15, 16] . Similarly, miRNAs have been shown to work both as facilitators and inhibitors of tumor metastasis [17] [18] [19] [20] [21] [22] .
Our findings directly contradict previous reports of high miR-183 expression in HCC [23] [24] [25] . In one study, it was shown that over-expression of miR-183/96/182 confers prooncogenic properties to HCC [24] . Another study showed that miR-183 is overexpressed in HCC, but not associated with changes in patient survival [23] . Whether the discrepancies among the results can be explained by miR-183 acting as tumor suppressor under some conditions and as pro-oncogene under others, awaits further study. 
